Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Sci Rep ; 12(1): 430, 2022 01 11.
Artículo en Inglés | MEDLINE | ID: mdl-35017550

RESUMEN

Obesity can disturb spermatogenesis and subsequently affect male fertility and reproduction. In our study, we aim to elucidate at which cellular level of adult spermatogenesis the detrimental effects of obesity manifest. We induced high fat diet (HFD) obesity in low-density lipoprotein receptor knock-out Leiden (Ldlr-/-.Leiden) mice, and studied the morphological structure of the testes and histologically examined the proportion of Sertoli cells, spermatocytes and spermatids in the seminiferous tubules. We examined sperm DNA damage and chromatin condensation and measured plasma levels of leptin, testosterone, cholesterol and triglycerides. HFD-induced obesity caused high plasma leptin and abnormal testosterone levels and induced an aberrant intra-tubular organisation (ITO) which is associated with an altered spermatids/spermatocytes ratio (2:1 instead of 3:1). Mice fed a HFD had a higher level of tubules in stages VII + VIII in the spermatogenic cycle. The stages VII + VII indicate crucial processes in spermatogenic development like initiation of meiosis, initiation of spermatid elongation, and release of fully matured spermatids. In conclusion, HFD-induced obese Ldlr-/-.Leiden mice develop an aberrant ITO and alterations in the spermatogenic cycle in crucial stages (stages VII and VII). Thereby, our findings stress the importance of lifestyle guidelines in infertility treatments.


Asunto(s)
Dieta Alta en Grasa/efectos adversos , Lipoproteínas LDL/genética , Obesidad/fisiopatología , Espermátides/crecimiento & desarrollo , Espermatogénesis , Animales , Colesterol/sangre , Modelos Animales de Enfermedad , Humanos , Leptina/sangre , Lipoproteínas LDL/deficiencia , Masculino , Meiosis , Ratones , Ratones Noqueados , Obesidad/sangre , Obesidad/etiología , Espermátides/metabolismo , Espermatocitos/crecimiento & desarrollo , Espermatocitos/metabolismo , Testículo/citología , Testículo/crecimiento & desarrollo , Testículo/metabolismo , Testosterona/sangre
2.
Int J Obes (Lond) ; 41(6): 935-944, 2017 06.
Artículo en Inglés | MEDLINE | ID: mdl-28220041

RESUMEN

OBJECTIVE: Midlife obesity affects cognition and increases risk of developing dementia. Recent data suggest that intake of the short chain fatty acid butyrate could improve memory function, and may protect against diet-induced obesity by reducing body weight and adiposity. SUBJECTS: We examined the impact of a high-fat diet (HFD) followed by intervention with 5% (w/w) dietary butyrate, on metabolism, microbiota, brain function and structure in the low-density-lipoprotein receptor knockout (LDLr-/-) mouse model in mid and late life. RESULTS: In mid-adult mice, 15 weeks of HFD-induced adiposity, liver fibrosis and neuroinflammation, increased systolic blood pressure and decreased cerebral blood flow, functional connectivity assessed with neuroimaging. The subsequent 2 months butyrate intervention restored these detrimental effects to chow-fed control levels. Both HFD and butyrate intervention decreased variance in fecal microbiota composition. In late-adult mice, HFD showed similar detrimental effects and decreased cerebral white and gray matter integrity, whereas butyrate intervention attenuated only metabolic parameters. CONCLUSION: HFD induces detrimental effects in mid- and late-adult mice, which can be attenuated by butyrate intervention. These findings are consistent with reported associations between midlife obesity and cognitive impairment and dementia in humans. We suggest that butyrate may have potential in prevention and treatment of midlife obesity.


Asunto(s)
Adiposidad/efectos de los fármacos , Butiratos/farmacología , Circulación Cerebrovascular/efectos de los fármacos , Trastornos del Conocimiento/tratamiento farmacológico , Dieta Alta en Grasa/efectos adversos , Inflamación/tratamiento farmacológico , Fármacos Neuroprotectores/farmacología , Animales , Trastornos del Conocimiento/fisiopatología , Modelos Animales de Enfermedad , Hipertensión/tratamiento farmacológico , Hipertensión/fisiopatología , Inflamación/fisiopatología , Cirrosis Hepática/tratamiento farmacológico , Cirrosis Hepática/fisiopatología , Masculino , Ratones , Ratones Obesos
3.
J Neurodegener Dis ; 2013: 531326, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-26316992

RESUMEN

Atherosclerosis and apolipoprotein E ε4 (APOE4) genotype are risk factors for Alzheimer's disease (AD) and cardiovascular disease (CVD). Sex differences exist in prevalence and manifestation of both diseases. We investigated sex differences respective to aging, focusing on cognitive parameters in apoE4 and apoE knockout (ko) mouse models of AD and CVD. Presynaptic density and neurogenesis were investigated immunohistochemically in male and female apoE4, apoE ko, and wild-type mice. Middle-aged female apoE4 mice showed decreased presynaptic density in the inner molecular layer of the dentate gyrus of the hippocampus. Middle-aged female apoE ko mice showed a trend towards increased neurogenesis in the hippocampus compared with wild-type mice. No differences in these parameters could be observed in middle-aged male mice. Specific harmful interactions between apoE4 and estrogen could be responsible for decreased presynaptic density in female apoE4 mice. The trend of increased neurogenesis found in female apoE ko mice supports previous studies suggesting that temporarily increased amount of synaptic contacts and/or neurogenesis is a compensatory mechanism for synaptic failure. To our knowledge, no other studies investigating presynaptic density in aging female apoE4 or apoE ko mice are available. Sex-specific differences between APOE genotypes could account for some sex differences in AD and CVD.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...